Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma

Sree Harsha Tirumani; Ann S. Lacasce; Heather A. Jacene

doi:10.1016/j.cpet.2014.12.005

Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma

Sree Harsha Tirumani, Ann S. Lacasce, Heather A. Jacene

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.

Original language	English (US)
Pages (from-to)	207-225
Number of pages	19
Journal	PET Clinics
Volume	10
Issue number	2
DOIs	https://doi.org/10.1016/j.cpet.2014.12.005
State	Published - Apr 1 2015
Externally published	Yes

Keywords

Diffuse large B-cell lymphoma
FDG-PET/CT
Hodgkin lymphoma
Interim PET/CT
Lymphoma

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2014.12.005

Cite this

@article{be07c7d287da4473a40f18721578b338,

title = "Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma",

abstract = "The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.",

keywords = "Diffuse large B-cell lymphoma, FDG-PET/CT, Hodgkin lymphoma, Interim PET/CT, Lymphoma",

author = "Tirumani, {Sree Harsha} and Lacasce, {Ann S.} and Jacene, {Heather A.}",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.cpet.2014.12.005",

language = "English (US)",

volume = "10",

pages = "207--225",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma

AU - Tirumani, Sree Harsha

AU - Lacasce, Ann S.

AU - Jacene, Heather A.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.

AB - The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.

KW - Diffuse large B-cell lymphoma

KW - FDG-PET/CT

KW - Hodgkin lymphoma

KW - Interim PET/CT

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84964296837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964296837&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2014.12.005

DO - 10.1016/j.cpet.2014.12.005

M3 - Review article

C2 - 25829087

AN - SCOPUS:84964296837

SN - 1556-8598

VL - 10

SP - 207

EP - 225

JO - PET Clinics

JF - PET Clinics

IS - 2

ER -

Role of 2-deoxy-2-[18F]-fluoro-d-glucose-PET/computed tomography in lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this